Pub Date : 2024-12-01Epub Date: 2024-12-04DOI: 10.1055/a-2298-0609
Wolfgang Hiddemann
The success story of haematology and oncology extends from Virchow's concept of "cellular pathology" to the possibilities of personalized cancer therapy, which molecular oncology offers today. This article highlights the beginnings and developments of chemotherapy, immunotherapy, as well as molecular oncology and psycho-oncology over the past 150 years.
{"title":"[Haematology and Oncology - A look back at 150 years].","authors":"Wolfgang Hiddemann","doi":"10.1055/a-2298-0609","DOIUrl":"10.1055/a-2298-0609","url":null,"abstract":"<p><p>The success story of haematology and oncology extends from Virchow's concept of \"cellular pathology\" to the possibilities of personalized cancer therapy, which molecular oncology offers today. This article highlights the beginnings and developments of chemotherapy, immunotherapy, as well as molecular oncology and psycho-oncology over the past 150 years.</p>","PeriodicalId":93975,"journal":{"name":"Deutsche medizinische Wochenschrift (1946)","volume":"149 24-25","pages":"1500-1506"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142782218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01Epub Date: 2024-10-22DOI: 10.1055/a-2194-3285
Viola Andresen, Peter Layer
Chronic constipation is one of the most common health disorders in all of medicine. Its extent ranges from mild discomfort, which is usually easy to improve, to severe functional limitations that may significantly reduce quality of life and may be refractory to various treatment approaches. Our understanding of the pathomechanism has grown considerably in recent years and has also led to important new therapeutic developments. The resulting treatment options and recommendations are presented in the current update of the S2k constipation guideline in an evidence-based and practical manner. The respective significance of traditional and recent drug developments is classified and categorized in modern "step-up" treatment strategies. In particular, numerous important aspects of everyday practice are addressed, such as questions on long-term treatment and therapeutic options in specific constellations (adequate treatment of constipation in older people, constipation during pregnancy, and drug-induced [especially opioid-induced]constipation).The most important new developments (i.e. new therapeutic approaches, but also re-evaluations of "traditional" laxatives and the importance of careful diagnostics in therapy-refractory patients) are summarized in this article.
{"title":"[Chronic constipation].","authors":"Viola Andresen, Peter Layer","doi":"10.1055/a-2194-3285","DOIUrl":"10.1055/a-2194-3285","url":null,"abstract":"<p><p>Chronic constipation is one of the most common health disorders in all of medicine. Its extent ranges from mild discomfort, which is usually easy to improve, to severe functional limitations that may significantly reduce quality of life and may be refractory to various treatment approaches. Our understanding of the pathomechanism has grown considerably in recent years and has also led to important new therapeutic developments. The resulting treatment options and recommendations are presented in the current update of the S2k constipation guideline in an evidence-based and practical manner. The respective significance of traditional and recent drug developments is classified and categorized in modern \"step-up\" treatment strategies. In particular, numerous important aspects of everyday practice are addressed, such as questions on long-term treatment and therapeutic options in specific constellations (adequate treatment of constipation in older people, constipation during pregnancy, and drug-induced [especially opioid-induced]constipation).The most important new developments (i.e. new therapeutic approaches, but also re-evaluations of \"traditional\" laxatives and the importance of careful diagnostics in therapy-refractory patients) are summarized in this article.</p>","PeriodicalId":93975,"journal":{"name":"Deutsche medizinische Wochenschrift (1946)","volume":"149 22","pages":"1324-1328"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142515190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01Epub Date: 2024-11-06DOI: 10.1055/a-2201-5412
Stefano Bassetti, Martin C Hirsch, Edouard Battegay
"Clinical reasoning" refers to all the thought processes that physicians use to make a diagnosis and determine a treatment and care plan. Artificial intelligence (AI) will enhance, improve, and accelerate human clinical diagnostic thinking, but it is unlikely to replace it. Its application in medicine has the potential to drastically reduce medical diagnostic errors and give doctors more time to care for their patients. Here, we provide an overview of some of the key elements of clinical diagnostic reasoning and the potential impacts of AI on clinical reasoning.
{"title":"[Clinical reasoning, the art of medicine and artificial intelligence].","authors":"Stefano Bassetti, Martin C Hirsch, Edouard Battegay","doi":"10.1055/a-2201-5412","DOIUrl":"10.1055/a-2201-5412","url":null,"abstract":"<p><p>\"Clinical reasoning\" refers to all the thought processes that physicians use to make a diagnosis and determine a treatment and care plan. Artificial intelligence (AI) will enhance, improve, and accelerate human clinical diagnostic thinking, but it is unlikely to replace it. Its application in medicine has the potential to drastically reduce medical diagnostic errors and give doctors more time to care for their patients. Here, we provide an overview of some of the key elements of clinical diagnostic reasoning and the potential impacts of AI on clinical reasoning.</p>","PeriodicalId":93975,"journal":{"name":"Deutsche medizinische Wochenschrift (1946)","volume":"149 23","pages":"1401-1410"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142590899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01Epub Date: 2024-10-22DOI: 10.1055/a-2136-4088
Julia Banken, Eyleen Reifarth, Stephan Braune
An effective patient handover is a core element of high-quality patient care. Communication during patient handover in the intensive care unit is particularly challenging due to the clinical complexity and rapid changes in patient trajectories, complex interdisciplinary and interprofessional interfaces, linguistic barriers, situational and structural disruptive factors, personnel stress factors as well as the communication and error culture of the teams. In addition to avoiding disruptive factors and creating optimal communication conditions and human resources, the use of standardized and structured handovers with the help of protocols and checklists, as recommended in the literature, plays a decisive role as part of a bundle of measures for effective and safe patient care.
{"title":"[Handover of intensive care patients].","authors":"Julia Banken, Eyleen Reifarth, Stephan Braune","doi":"10.1055/a-2136-4088","DOIUrl":"https://doi.org/10.1055/a-2136-4088","url":null,"abstract":"<p><p>An effective patient handover is a core element of high-quality patient care. Communication during patient handover in the intensive care unit is particularly challenging due to the clinical complexity and rapid changes in patient trajectories, complex interdisciplinary and interprofessional interfaces, linguistic barriers, situational and structural disruptive factors, personnel stress factors as well as the communication and error culture of the teams. In addition to avoiding disruptive factors and creating optimal communication conditions and human resources, the use of standardized and structured handovers with the help of protocols and checklists, as recommended in the literature, plays a decisive role as part of a bundle of measures for effective and safe patient care.</p>","PeriodicalId":93975,"journal":{"name":"Deutsche medizinische Wochenschrift (1946)","volume":"149 22","pages":"1348-1355"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142515193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01Epub Date: 2024-10-22DOI: 10.1055/a-2198-0363
Malte P Bartram, Bodo B Beck, Roman-Ulrich Müller
While genetic kidney diseases were long regarded as a rare cause of kidney failure, it has been shown in recent years that they account for a relevant proportion of cases. In cohorts of kidney transplant recipients, a monogenic cause is found in up to 30% of cases. Identifying the genetic cause of kidney disease has become much easier thanks to technological advances in DNA sequencing. The focus has now shifted to understanding the significance of the findings and identifying diagnostic gaps. It is still not possible to clarify all CKD cases of unclear aetiology. Besides very effective generic treatments for monogenic kidney disease (e.g., ACE-inhibitor use in Alport Syndrome), increasing knowledge of the pathophysiology of genetic kidney diseases has led to a growing number of targeted therapies. These include the treatment of ADPKD with Tolvaptan, which has now been in use for 10 years. Recently, exciting, and completely new approaches have been added, such as the first siRNA therapies in nephrology for primary hyperoxaluria type 1, the targeted treatment of hyperphagia in Bardet-Biedl syndrome, the therapy of APOL1-associated kidney disease or the use of the HIF-2 antagonist Belzutifan for renal cell carcinoma associated with Von-Hippel-Lindau syndrome. The new possibilities in the treatment of patients with genetic kidney diseases have also clearly revealed deficits in current patient care. Centers of excellence with extensive experience in this area therefore play an important role in improving care. This also applies to the further training of colleagues in the field. In Germany, the National Action Alliance for People with Rare Diseases (NAMSE) and the nationwide establishment of - to date - 36 centers for rare diseases play an important role in this regard.
{"title":"[Genetics in nephrology - any news?]","authors":"Malte P Bartram, Bodo B Beck, Roman-Ulrich Müller","doi":"10.1055/a-2198-0363","DOIUrl":"https://doi.org/10.1055/a-2198-0363","url":null,"abstract":"<p><p>While genetic kidney diseases were long regarded as a rare cause of kidney failure, it has been shown in recent years that they account for a relevant proportion of cases. In cohorts of kidney transplant recipients, a monogenic cause is found in up to 30% of cases. Identifying the genetic cause of kidney disease has become much easier thanks to technological advances in DNA sequencing. The focus has now shifted to understanding the significance of the findings and identifying diagnostic gaps. It is still not possible to clarify all CKD cases of unclear aetiology. Besides very effective generic treatments for monogenic kidney disease (e.g., ACE-inhibitor use in Alport Syndrome), increasing knowledge of the pathophysiology of genetic kidney diseases has led to a growing number of targeted therapies. These include the treatment of ADPKD with Tolvaptan, which has now been in use for 10 years. Recently, exciting, and completely new approaches have been added, such as the first siRNA therapies in nephrology for primary hyperoxaluria type 1, the targeted treatment of hyperphagia in Bardet-Biedl syndrome, the therapy of APOL1-associated kidney disease or the use of the HIF-2 antagonist Belzutifan for renal cell carcinoma associated with Von-Hippel-Lindau syndrome. The new possibilities in the treatment of patients with genetic kidney diseases have also clearly revealed deficits in current patient care. Centers of excellence with extensive experience in this area therefore play an important role in improving care. This also applies to the further training of colleagues in the field. In Germany, the National Action Alliance for People with Rare Diseases (NAMSE) and the nationwide establishment of - to date - 36 centers for rare diseases play an important role in this regard.</p>","PeriodicalId":93975,"journal":{"name":"Deutsche medizinische Wochenschrift (1946)","volume":"149 22","pages":"1361-1366"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142515192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01Epub Date: 2024-10-22DOI: 10.1055/a-2165-5788
Rainer Gloeckl, Inga Jarosch, Andreas Rembert Koczulla
There is a legal entitlement to participate in outpatient exercise groups in accordance with the German Social Code (Book IX) which regulates and facilitates prescriptions for patients with chronic respiratory diseases. A medical examination with specific inclusion and exclusion criteria prior to admission to an exercise group ensures safe participation.Traditional outpatient exercise groups are conducted in face-to-face groups for 60 to 90 minutes, once a week, with structured warm-up, main and cool-down phases. In addition, since the coronavirus pandemic, the introduction of online exercise groups via videoconferencing has enabled flexible participation (even without a prescription). To date, more than 11,000 German patients have participated in online exercise groups since 2021.Scientific evidence confirms the significant benefits of regular exercise, such as improved physical performance and reduced breathlessness. The psychosocial benefits and the promotion of self-efficacy are additionally supported by the supervision of a specialized trainer. Regular exercise (e.g. in outpatient exercise groups) is an inexpensive and very effective form of therapy to improve the quality of life of people with chronic respiratory diseases.
{"title":"[Outpatient exercise training for chronic lung disease - for whom, how and why?]","authors":"Rainer Gloeckl, Inga Jarosch, Andreas Rembert Koczulla","doi":"10.1055/a-2165-5788","DOIUrl":"https://doi.org/10.1055/a-2165-5788","url":null,"abstract":"<p><p>There is a legal entitlement to participate in outpatient exercise groups in accordance with the German Social Code (Book IX) which regulates and facilitates prescriptions for patients with chronic respiratory diseases. A medical examination with specific inclusion and exclusion criteria prior to admission to an exercise group ensures safe participation.Traditional outpatient exercise groups are conducted in face-to-face groups for 60 to 90 minutes, once a week, with structured warm-up, main and cool-down phases. In addition, since the coronavirus pandemic, the introduction of online exercise groups via videoconferencing has enabled flexible participation (even without a prescription). To date, more than 11,000 German patients have participated in online exercise groups since 2021.Scientific evidence confirms the significant benefits of regular exercise, such as improved physical performance and reduced breathlessness. The psychosocial benefits and the promotion of self-efficacy are additionally supported by the supervision of a specialized trainer. Regular exercise (e.g. in outpatient exercise groups) is an inexpensive and very effective form of therapy to improve the quality of life of people with chronic respiratory diseases.</p>","PeriodicalId":93975,"journal":{"name":"Deutsche medizinische Wochenschrift (1946)","volume":"149 22","pages":"1367-1371"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142515196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01Epub Date: 2024-11-06DOI: 10.1055/a-2179-9964
Edouard Battegay
{"title":"[Human versus Artificial Intelligence: who makes the decision?]","authors":"Edouard Battegay","doi":"10.1055/a-2179-9964","DOIUrl":"https://doi.org/10.1055/a-2179-9964","url":null,"abstract":"","PeriodicalId":93975,"journal":{"name":"Deutsche medizinische Wochenschrift (1946)","volume":"149 23","pages":"1379-1380"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142590903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01Epub Date: 2024-11-06DOI: 10.1055/a-2406-6891
Oliver Kolks, Stefan Stahlhoff, Michael Lichtenberg
Introduction: Renal infarction is a rare cause for an acute renal failure. At the time being, there is no sufficient correlation to the consumption of cannabis described.
Case history: A 40-year-old male patient presented to our emergency room because of pain in the right renal bed.
Examination and findings: The duplex ultrasound showed no ectasia, but the computed tomography confirmed a renal infraction on the right side. The further diagnostics gave no indication of a classical pathogenesis, but there was a constant consumption of cannabis documented.
Therapy and course: We decided for a conservative treatment with analgesia, diagnostic laboratory controls and anticoagulants because of the prolonged process. The complaints decreased.
Discussion: The correlation between thrombo-embolic events and the consumption of cannabis has to be more explored because of its recent legalization in Germany. It should be considered as a cardiovascular risk factor. Until today there are no recommendations for the anticoagulants.
{"title":"[Renal infarction by cannabis consumption].","authors":"Oliver Kolks, Stefan Stahlhoff, Michael Lichtenberg","doi":"10.1055/a-2406-6891","DOIUrl":"https://doi.org/10.1055/a-2406-6891","url":null,"abstract":"<p><strong>Introduction: </strong> Renal infarction is a rare cause for an acute renal failure. At the time being, there is no sufficient correlation to the consumption of cannabis described.</p><p><strong>Case history: </strong> A 40-year-old male patient presented to our emergency room because of pain in the right renal bed.</p><p><strong>Examination and findings: </strong> The duplex ultrasound showed no ectasia, but the computed tomography confirmed a renal infraction on the right side. The further diagnostics gave no indication of a classical pathogenesis, but there was a constant consumption of cannabis documented.</p><p><strong>Therapy and course: </strong> We decided for a conservative treatment with analgesia, diagnostic laboratory controls and anticoagulants because of the prolonged process. The complaints decreased.</p><p><strong>Discussion: </strong> The correlation between thrombo-embolic events and the consumption of cannabis has to be more explored because of its recent legalization in Germany. It should be considered as a cardiovascular risk factor. Until today there are no recommendations for the anticoagulants.</p>","PeriodicalId":93975,"journal":{"name":"Deutsche medizinische Wochenschrift (1946)","volume":"149 23","pages":"1420-1422"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142590907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01Epub Date: 2024-10-22DOI: 10.1055/a-2372-1157
Cathrin Kodde, Leif Erik Sander
Rsv (respiratory syncytial virus): RSV is a common cause of respiratory tract infections, posing a risk of severe disease, particularly for newborns and infants, as well as in older individuals with pre-existing conditions. Two safe and effective RSV vaccines were approved in 2023. These vaccines elicit protective antibodies and offer robust protection with no additional benefit from annual boosters. Both vaccines have been approved for individuals aged 60 years and older, while one of the vaccines has also been approved in pregnant women to elicit maternal immunity for passive protection of the unborn child. In Germany, RSV vaccination is currently recommended for all individuals aged 75 years and older, as well as people aged 60-74 years of age with severe underlying conditions. PNEUMOCOCCAL INFECTION: Streptococcus pneumoniae is a primary cause of community-acquired pneumonia (CAP). Since early 2022, a 20-valent conjugate vaccine (PCV20) is approved and recommended for people over 60 years of age and individuals over 18 years of age with risk factors. PCV20 replaces the 23-valent polysaccharide vaccine (PPV23) previously recommended for those over 60 years of age.
Pertussis: Although viewed primarily as a childhood disease, the majority of infections affect adults. Patients with chronic respiratory diseases are at a higher risk for severe clinical course of pertussis infection. It has therefore been recommended that all adults should get a pertussis booster with their next scheduled tetanus vaccination, given as a combination vaccine (Tdap). For risk groups (healthcare personnel, community facilities) a booster vaccination every 10 years is recommended.
Herpes zoster: Herpes Zoster (shingles) is caused by the varicella-zoster virus, and reactivations can lead to painful skin lesions and potential complications such as herpes zoster oticus, meningitis, or postherpetic neuralgia. People with chronic lung diseases such as COPD or asthma are at increased risk of herpes zoster-related complications. A recombinant adjuvanted inactivated vaccine was approved in 2018 and offers robust protection against herpes zoster and its complications. The vaccine is recommended for all people over 60 years of age and for certain risk groups over 50 years of age.
{"title":"[Vaccinations in pulmonary diseases - part 2: herpes zoste, RSV, pneumococcal infection and pertussis].","authors":"Cathrin Kodde, Leif Erik Sander","doi":"10.1055/a-2372-1157","DOIUrl":"https://doi.org/10.1055/a-2372-1157","url":null,"abstract":"<p><strong>Rsv (respiratory syncytial virus): </strong>RSV is a common cause of respiratory tract infections, posing a risk of severe disease, particularly for newborns and infants, as well as in older individuals with pre-existing conditions. Two safe and effective RSV vaccines were approved in 2023. These vaccines elicit protective antibodies and offer robust protection with no additional benefit from annual boosters. Both vaccines have been approved for individuals aged 60 years and older, while one of the vaccines has also been approved in pregnant women to elicit maternal immunity for passive protection of the unborn child. In Germany, RSV vaccination is currently recommended for all individuals aged 75 years and older, as well as people aged 60-74 years of age with severe underlying conditions. PNEUMOCOCCAL INFECTION: <i>Streptococcus pneumoniae</i> is a primary cause of community-acquired pneumonia (CAP). Since early 2022, a 20-valent conjugate vaccine (PCV20) is approved and recommended for people over 60 years of age and individuals over 18 years of age with risk factors. PCV20 replaces the 23-valent polysaccharide vaccine (PPV23) previously recommended for those over 60 years of age.</p><p><strong>Pertussis: </strong>Although viewed primarily as a childhood disease, the majority of infections affect adults. Patients with chronic respiratory diseases are at a higher risk for severe clinical course of pertussis infection. It has therefore been recommended that all adults should get a pertussis booster with their next scheduled tetanus vaccination, given as a combination vaccine (Tdap). For risk groups (healthcare personnel, community facilities) a booster vaccination every 10 years is recommended.</p><p><strong>Herpes zoster: </strong>Herpes Zoster (shingles) is caused by the varicella-zoster virus, and reactivations can lead to painful skin lesions and potential complications such as herpes zoster oticus, meningitis, or postherpetic neuralgia. People with chronic lung diseases such as COPD or asthma are at increased risk of herpes zoster-related complications. A recombinant adjuvanted inactivated vaccine was approved in 2018 and offers robust protection against herpes zoster and its complications. The vaccine is recommended for all people over 60 years of age and for certain risk groups over 50 years of age.</p>","PeriodicalId":93975,"journal":{"name":"Deutsche medizinische Wochenschrift (1946)","volume":"149 22","pages":"1372-1376"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142515198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01Epub Date: 2024-11-06DOI: 10.1055/a-2199-8816
Martin K Kuhlmann, Susanne Fleig
Dietary recommendations for patients on dialysis are changing as our understanding of enteral microbiotal metabolism and bioavailability of nutrients from food improves.A diet low in phosphate and potassium is recommended for patients on hemodialysis. However, the absolute content does not reflect bioavailability: How much phosphate or potassium is taken up depends on food source (plant vs. animal) and to which grade it is processed. While both are nearly 100% bioavailable from industrially processed foods (additives such as dipotassium-phosphate and other salts), a much lower proportion is taken up from unprocessed plant foods high in fibre (ca. 20-40%). The DIET-HD study showed no significant association between dietary potassium and serum potassium in > 8 000 dialysis patients; and those with the highest low-processed, fresh plant-food consumption have the best survival. Dietary fibre improves colon transit time and thereby lessens symptoms of constipation. A diet low in sodium improves blood pressure and volume management in dialysis patients. The energy and protein requirements on dialysis are high: 25-35 kcal and 1-1,2 g protein per kg body weight per day (in relation to "ideal" body weight, if patient is overweight). Protein energy wasting is associated with higher stages of kidney disease, and malnutrition is associated with worse survival on dialysis. Nutritional status should be assessed on a regular basis using validated scores, and malnutrition should be addressed and treated.
{"title":"[Nutrition for patients on dialysis].","authors":"Martin K Kuhlmann, Susanne Fleig","doi":"10.1055/a-2199-8816","DOIUrl":"https://doi.org/10.1055/a-2199-8816","url":null,"abstract":"<p><p>Dietary recommendations for patients on dialysis are changing as our understanding of enteral microbiotal metabolism and bioavailability of nutrients from food improves.A diet low in phosphate and potassium is recommended for patients on hemodialysis. However, the absolute content does not reflect bioavailability: How much phosphate or potassium is taken up depends on food source (plant vs. animal) and to which grade it is processed. While both are nearly 100% bioavailable from industrially processed foods (additives such as dipotassium-phosphate and other salts), a much lower proportion is taken up from unprocessed plant foods high in fibre (ca. 20-40%). The DIET-HD study showed no significant association between dietary potassium and serum potassium in > 8 000 dialysis patients; and those with the highest low-processed, fresh plant-food consumption have the best survival. Dietary fibre improves colon transit time and thereby lessens symptoms of constipation. A diet low in sodium improves blood pressure and volume management in dialysis patients. The energy and protein requirements on dialysis are high: 25-35 kcal and 1-1,2 g protein per kg body weight per day (in relation to \"ideal\" body weight, if patient is overweight). Protein energy wasting is associated with higher stages of kidney disease, and malnutrition is associated with worse survival on dialysis. Nutritional status should be assessed on a regular basis using validated scores, and malnutrition should be addressed and treated.</p>","PeriodicalId":93975,"journal":{"name":"Deutsche medizinische Wochenschrift (1946)","volume":"149 23","pages":"1431-1442"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142590905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}